Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Нестероидные противовоспалительные препараты и кардиопротективные эффекты ацетилсалициловой кислоты: селективный подход к выбору ингибиторов циклооксигеназы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ломакин Н.В., Груздев А.К. Эффективность и безопасность нестероидного противовоспалительного средства лорноксикам у больных с острым коронарным синдромом без подъема сегмента ST. Кардиология и сердечно-сосудистая хирургия. 2010; 1: 19.
2. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler Thromb Vasc Biol 1999; 19: 646–55.
3. Baron JA et al. New Engl J Med 2003; 348: 891–9.
4. Belton O, Fitzgerald DJ. Cyclooxygenase isoforms and atherosclerosis. Exp Rev Mol Med 2003; 5: 1–18.
5. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur Heart J 1993; 14: 951–7.
6. Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation 2002; 105: 1816–23.
7. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17; Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280–8.
8. Chan CC, Boyce S, Brideau C et al. Rofecoxib (Vioxx, MK-0966; 4-[4'-methylsulfonylphenyl]-3-phenyl-2-[5H]-furanone): a potent and orally active cyclooxygenase and biochemical profiles.
J Pharmacol Exp Ther 1999; 290: 551–60.
9. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–21.
10. Esser R, Berry C, Du Z et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005; 144: 538–50.
11. Fitzgerald GA, Austin S, Egan K et al. Cyclooxygenase products and atherothrombosis. Ann Med 2000; 32 (Suppl. 1): 21–6.
12. Cipollone F. Arterioscler Thromb Vasc Biol 2004; 24: 246.
13. Gum PA, Kottke-Marchant K, Poggio E et al. Profile and prevalence of aspirin resistence in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–4.
14. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin. Could it be thromboxane A2. Circulation 2002; 105: 1620–2.
15. Howard PA. Aspirin resistance Ann Pharmacotherapy 2002; 36: 1620–4.
16. Ko D, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002; 143: 475–81.
17. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280–8.
18. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002; 13: 497–504.
19. Murray CJ, Lopez AD. The global burden of disease, 1990–2020. Nat Med 1998; 4: 1241–3.
20. Lomakin N, Gruzdev A. Antinflammatory Activity and COX-1 Receptor Competition in Patients With Acute Coronary Syndrome Without ST-segment Elevation Treated With Nonselective COX-Inhibitor And Low-Dose Aspirin. J Am Coll Cardiol 2011; 57: E951.
21. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7–13.
22. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs Chest 2008; 133: 199S–233S.
23. Rocca B, Secchiero P, Giabattoni G et al. Cycloxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. PNAS 2002; 99: 7634–9.
24. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 104: 115–26.
25. Schonbeck U, Sukhova GK, Graber P et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281–91.
26. Segev G, Katz RJ. Selective COX-2 inhibitors and risk of cardiovascular events. Hosp Physician 2004; 40: 39–46.
27. Tacconelli S, Capone ML, Sciulli MG et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002; 18: 503–11.
28. Tousoulis D, Davies G, Stefanadis C et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993–7.
29. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schor K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistence. Lancet 1999; 353: 900.
30. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888–99.
2. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler Thromb Vasc Biol 1999; 19: 646–55.
3. Baron JA et al. New Engl J Med 2003; 348: 891–9.
4. Belton O, Fitzgerald DJ. Cyclooxygenase isoforms and atherosclerosis. Exp Rev Mol Med 2003; 5: 1–18.
5. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur Heart J 1993; 14: 951–7.
6. Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation 2002; 105: 1816–23.
7. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17; Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280–8.
8. Chan CC, Boyce S, Brideau C et al. Rofecoxib (Vioxx, MK-0966; 4-[4'-methylsulfonylphenyl]-3-phenyl-2-[5H]-furanone): a potent and orally active cyclooxygenase and biochemical profiles.
J Pharmacol Exp Ther 1999; 290: 551–60.
9. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–21.
10. Esser R, Berry C, Du Z et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005; 144: 538–50.
11. Fitzgerald GA, Austin S, Egan K et al. Cyclooxygenase products and atherothrombosis. Ann Med 2000; 32 (Suppl. 1): 21–6.
12. Cipollone F. Arterioscler Thromb Vasc Biol 2004; 24: 246.
13. Gum PA, Kottke-Marchant K, Poggio E et al. Profile and prevalence of aspirin resistence in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–4.
14. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin. Could it be thromboxane A2. Circulation 2002; 105: 1620–2.
15. Howard PA. Aspirin resistance Ann Pharmacotherapy 2002; 36: 1620–4.
16. Ko D, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002; 143: 475–81.
17. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280–8.
18. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002; 13: 497–504.
19. Murray CJ, Lopez AD. The global burden of disease, 1990–2020. Nat Med 1998; 4: 1241–3.
20. Lomakin N, Gruzdev A. Antinflammatory Activity and COX-1 Receptor Competition in Patients With Acute Coronary Syndrome Without ST-segment Elevation Treated With Nonselective COX-Inhibitor And Low-Dose Aspirin. J Am Coll Cardiol 2011; 57: E951.
21. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7–13.
22. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs Chest 2008; 133: 199S–233S.
23. Rocca B, Secchiero P, Giabattoni G et al. Cycloxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. PNAS 2002; 99: 7634–9.
24. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 104: 115–26.
25. Schonbeck U, Sukhova GK, Graber P et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281–91.
26. Segev G, Katz RJ. Selective COX-2 inhibitors and risk of cardiovascular events. Hosp Physician 2004; 40: 39–46.
27. Tacconelli S, Capone ML, Sciulli MG et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002; 18: 503–11.
28. Tousoulis D, Davies G, Stefanadis C et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993–7.
29. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schor K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistence. Lancet 1999; 353: 900.
30. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888–99.
Авторы
Н.В.Ломакин, А.К.Груздев
ФГУ Центральная клиническая больница с поликлиникой Управления делами Президента РФ, Москва
ФГУ Центральная клиническая больница с поликлиникой Управления делами Президента РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.